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The balanced translocation between the short arm of 
chromosome 12 and the long arm of the chromosome 
18 -t(12;18)(p13;q12)- has been described in a patient 
with acute myeloid leukemia secondary to 
myelodysplastic syndrome. The key event in the 
t(12;18)(p13;q12) involving ETV6 is the 
overexpression of SETBP1 (18q12), a gene located 
close to the breakpoint (Cristobal et al., 2010). 
 
Partial karyotype of a patient with AML-M5 and a 
t(12;18)(p13;q12). Derivative chromosomes are indicated by 
arrows. 
Clinics and pathology 
Disease 
Acute Myeloid Leukemia (AML-M5) secondary to 
Myelodysplastic Syndrome (MDS). 
Epidemiology 
This is a rare chromosomal rearrangement, 
characterized at molecular level in only one AML 
patient to date. 
Clinics 
A 76-year-old caucasian man was diagnosed with  
 
myelodysplastic syndrome (MDS).  
Disease evaluation of the patient 3 years after the 
diagnosis showed anorexia, perspiration and loss of 7
kg. 
Cytology 
Blast morphology was indicative of acute monocytic 
leukemia. 
Pathology 
Bone marrow aspirate was hypercellular, showing 80% 
blasts. 
Treatment 
The patient received standard induction chemotherapy 
for two months, and had partial remission at the next 
evaluation. 
Evolution 
The patient relapsed 2 months later and, eventually, 
died. 
Prognosis 
SETBP1 overexpression is a marker of poor prognosis 
in AML, with special relevance in the subgroup of 
elderly patients (Cristobal et al., 2010). 
Genetics 
Note 
The t(12;18)(p13;q12) involves the ETV6 gene 
(12p13), a transcription factor frequently rearranged in 
both myeloid and lymphoid leukemias.  
More than 15 ETV6 fusion gene partners have been 
described. Most translocations involving ETV6 
generate fusion genes that lead to the activation of 
either unrelated transcription factors or kinases (Cools 
et al., 2002).  
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However, in some cases functionally significant fusion  
could not be identified and an alternative mechanism 
consisting in the ectopic expression of genes located 
close to the breakpoints has been described. This 
molecular mechanism, which has been described 
mainly in lymphoid leukemias and lymphomas, is an 
uncommon mechanism in myeloid leukemias, although 
some examples have been reported (Cools et al., 2002; 
Odero et al., 2002; Nucifora et al., 2006). The key 
event in the t(12;18)(p13;q12) involving ETV6 is the 
overexpression of SETBP1 (18q12), a gene located 
close to the breakpoint (Cristobal et al., 2010). 
Cytogenetics 
Cytogenetics morphological 
t(12;18)(p13;q12) as the sole abnormality; +19 as an 
additional anomaly at relapse. 
Cytogenetics molecular 
FISH showed that the breakpoint on 12p13 was located 
between exons 2 and 3 of ETV6.  
To confirm the position of the breakpoint on 
chromosome 18, BACs located at 18q12 were used as 
probes in FISH experiments. Analysis on BM cells of 
the patient showed that one signal hybridized to the 
normal chromosome 18, and the other split and 
hybridized to both der(18) and der(12). FISH showed 
that the breakpoint was located 5' and close to the 
SETBP1 gene. 
Probes 
The order of the probes on 18q12 is centromere- 
840B16-937P23-252G8-941F5-telomere.  
To map the breakpoints bacterial artificial 
chromosomes obtained from the Roswell Park Cancer 
Institute (Buffalo, NY) were used and labeled with 
SpectrumGreen-dUTP or SpectrumOrange-dUTP. 
Additional anomalies 
The presence of a trisomy 19 in one clone suggests tha  
SETBP1 overexpression, as a consequence of position 
effects, could cooperate with other additional 
aberrations to the development of AML in this patient. 
Genes involved and proteins 
Note 
The key event in the t(12;18)(p13;q12) involving ETV6 
is the overexpression of SETBP1 (18q12), a gene 





The ETV6 gene encodes a transcription factor 
frequently rearranged in both myeloid and lymphoid 
leukemias.  
Translocations involving this gene mostly result in the 
generation of in-frame fusion genes between different 
domains of ETV6 and partner genes encoding either 
kinases or transcription factors with importance in 
cancer.  
However, in some cases functionally significant fusion  
could not be detected, and the deregulation of the 
expression of oncogenes located close to the 
breakpoints has been described as an alternative 
leukemogenic mechanism (Cools et al., 2002). 
 
FISH analysis indicating the breakpoint on 18q12: probe RP11-252G8 (green) splits and hybridizes in both der(18) and der(12). 











The SETBP1 gene encodes a protein of 1542 amino 
acids and a molecular weight of 170 kDa, with a 
predominantly nuclear location (Minakuchi et al., 2001; 
Cristobal et al., 2010).  
The protein contains a region homologous to the 
dimerization domain of SKI, and a SET-binding region 
(Minakuchi et al., 2001).  
The protein SET (I2PP2A/TAF-Iβ) inhibits PP2A, a 
phosphatase with a pivotal role in cancer as a tumor 
supressor (Mumby, 2007), through the phosphorylation 
of the PP2Ac tyrosine-307 (Li et al., 1996).  
Interestingly, activation of SETBP1 expression by 
retroviral integration in hematopoietic progenitor cells 
has been reported to confer a growth advantage leading 
to clonal expansion (Ott et al., 2006). Moreover, it has 
been reported that SETBP1 overexpression protects 
SET from protease cleavage, increasing the amount of 
full-length SET protein, and leading to the formation of 
a SETBP1-SET-PP2A complex that results in PP2A 
inhibition, and therefore promotes the proliferation and 
expansion of leukemic cells (Cristobal et al., 2010). 
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